lenvatinib and cuprous-sulfide

Lenvatinib (LT) is gradually replacing sorafenib as an alternative targeted drug against advanced hepatocellular carcinoma (HCC). However, the anticancer effects of LT are still limited because of its low cytotoxicity, multidrug resistance (MDR), and tumor relapse. Herein, we constructed a smart biophotonic nanoplatform to overcome the barriers preventing high performance. LT and copper sulfide nanocrystals (Cu

Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Capsules; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Copper; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Materials Testing; Mice; Mice, Inbred BALB C; Mice, Nude; Particle Size; Phenylurea Compounds; Photothermal Therapy; Polylactic Acid-Polyglycolic Acid Copolymer; Quinolines; Sulfides; Tumor Cells, Cultured